A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

• Status: Active, not recruiting
• Trial end date: 2022-03-04
• Target enrollment: 0
• Participant gender: All

Summary

The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with JIA from 2 years to less than 18 years old.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Participants must have had a diagnosis of active JIA (polyarticular, extended oligoarticular, or enthesitis-related juvenile idiopathic arthritis [ERA] including JPsA).

• Participants must have had an inadequate response to at least one conventional or biologic disease-modifying antirheumatic drug (DMARD).

Exclusion Criteria:

• Participants must not have systemic JIA, with or without active systemic features.

• Participants must not have persistent oligoarticular arthritis.

• Participants must not have been previously treated with a Janus kinase (JAK) inhibitor.